Vericel (NASDAQ:VCEL) Shares Down 3.8% - What's Next?

Shares of Vericel Co. (NASDAQ:VCEL - Get Free Report) fell 3.8% on Monday . The company traded as low as $41.12 and last traded at $41.05. 132,552 shares were traded during trading, a decline of 68% from the average session volume of 415,214 shares. The stock had previously closed at $42.67.

Analyst Upgrades and Downgrades

VCEL has been the topic of a number of recent analyst reports. Wall Street Zen lowered Vericel from a "hold" rating to a "sell" rating in a research note on Monday, May 12th. Truist Financial lowered their price objective on shares of Vericel from $61.00 to $51.00 and set a "buy" rating for the company in a research report on Friday, April 11th. Stephens reissued an "overweight" rating and issued a $67.00 price target on shares of Vericel in a report on Monday. Finally, HC Wainwright reaffirmed a "buy" rating and set a $60.00 price objective on shares of Vericel in a report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Vericel presently has a consensus rating of "Moderate Buy" and a consensus target price of $61.14.

Vericel Stock Performance

The business's 50-day moving average is $41.47 and its two-hundred day moving average is $49.61. The firm has a market capitalization of $2.09 billion, a price-to-earnings ratio of 693.28 and a beta of 1.33.

Vericel (NASDAQ:VCEL - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biotechnology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.14). Vericel had a return on equity of 1.48% and a net margin of 1.56%. The business had revenue of $52.60 million for the quarter, compared to analyst estimates of $53.86 million. During the same period in the previous year, the business posted ($0.08) EPS. The business's quarterly revenue was up 2.6% compared to the same quarter last year. Analysts forecast that Vericel Co. will post 0.14 EPS for the current year.

Insider Buying and Selling at Vericel

In other news, CEO Dominick Colangelo sold 24,850 shares of the business's stock in a transaction dated Thursday, April 10th. The stock was sold at an average price of $41.89, for a total value of $1,040,966.50. Following the sale, the chief executive officer now directly owns 260,354 shares in the company, valued at $10,906,229.06. The trade was a 8.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 5.20% of the company's stock.

Institutional Trading of Vericel

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Invesco Ltd. boosted its stake in shares of Vericel by 1.6% during the 1st quarter. Invesco Ltd. now owns 2,273,494 shares of the biotechnology company's stock worth $101,443,000 after buying an additional 35,345 shares during the last quarter. Congress Asset Management Co. boosted its position in Vericel by 1.6% during the first quarter. Congress Asset Management Co. now owns 1,476,718 shares of the biotechnology company's stock valued at $65,891,000 after purchasing an additional 22,579 shares during the last quarter. GW&K Investment Management LLC grew its stake in Vericel by 12.4% in the first quarter. GW&K Investment Management LLC now owns 1,432,434 shares of the biotechnology company's stock valued at $63,915,000 after purchasing an additional 158,470 shares in the last quarter. Geneva Capital Management LLC increased its position in shares of Vericel by 24.2% during the 1st quarter. Geneva Capital Management LLC now owns 1,365,744 shares of the biotechnology company's stock worth $60,939,000 after purchasing an additional 265,956 shares during the last quarter. Finally, Wellington Management Group LLP raised its stake in shares of Vericel by 5.8% during the 1st quarter. Wellington Management Group LLP now owns 1,363,644 shares of the biotechnology company's stock worth $60,846,000 after purchasing an additional 74,723 shares in the last quarter.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.